Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Once again, Dupixent finished in second place with an impressions SOV of 5.40% and 2.8 billion impressions. Notably, the ...

and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:SNY) / Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Dupixent ...

with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. Ebglyss was also approved in the European Union in 2023 and ...

Last month, the FDA approved Ebglyss, a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis ...

Before you start treatment with Dupixent, tell your doctor and pharmacist ... It’s important to note that atopic dermatitis (a type of eczema) may be improved or worsened by exposure to the ...

WNBA legend and all-time scoring leader Diana Taurasi shows she' passionate about off-court causes involving health and wellbeing.

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...